Hanx Biopharmaceuticals Reports the First Patient Dosing with HX044 in P-I Clinical Evaluation
Shots:
- Hanx Biopharmaceuticals has dosed the first patient with HX044 under its P-I clinical evaluation for treating solid tumors
- The dose escalation & expansion P-I/IIa (HX044-I-01) trial will assess safety, tolerability, PK profile & initial efficacy of HX044 for the treatment of advanced solid tumor malignancies
- HX044 is a first-in-class bispecific antibody and next-generation CTLA-4 immunotherapy, being designed for PD-1-resistant tumors like NSCLC, renal cell carcinoma, melanoma & gastrointestinal cancers
Ref: Prnewswire | Image: Hanx Biopharmaceuticals
Related News:- Xgene Pharmaceutical Reports Results from P-IIb Trial of XG005 for Post-Surgical Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
